Prof David Vetrie and team have identified two “routes” (TR1 & TR2) leading to CML - helping explain differences in patient outcomes. 💡
Now, with a second Project Grant, the team is building on this to develop more targeted therapies. 🧡
Read more: www.leukaemiauk.org.uk/the-road-to-...
